Overview of the Agenus Inc. Class Action Lawsuit
Agenus Inc. (NASDAQ: AGEN) is currently embroiled in a class action lawsuit that has attracted considerable attention from investors. This legal action stems from allegations regarding the effectiveness of their immuno-oncology therapies, which raises important questions about the company's practices and how transparent they are.
Details of the Class Action Lawsuit
This lawsuit focuses on the time frame between January 23, 2023, and July 17, 2024. Investors who bought shares of AGEN during this period might have claims against the company, based on allegations that misleading statements and omissions were made regarding the effectiveness of their therapies.
Allegations Against Agenus
The complaint asserts that throughout the class period, the defendants issued materially false and misleading statements. In particular, it is alleged that the combination therapy involving botensilimab and balstilimab was presented as being more effective than it actually is. This misrepresentation likely inflated the company's stock prices, leading to financial harm for investors.
What This Means for Shareholders
If you hold shares and feel affected by these alleged misrepresentations, it is vital to understand your rights. Submitting a claim could help you recover losses suffered during the class period. You don’t need any prior experience or special status to file a claim, and interested investors are urged to get in touch for more information.
Steps for Interested Investors
One key deadline for investors is November 5, 2024; this is when individuals can apply to be lead plaintiffs in the case. Taking this proactive step can help ensure your interests are represented. Additionally, once you register, you’ll have access to portfolio monitoring software that will keep you updated throughout the lawsuit.
The Benefits of Legal Support
The Gross Law Firm, known nationally for its work in class action litigations, is focused on representing investors seeking justice for losses due to misleading practices. Their goal is to protect investor rights and hold corporations accountable for any misrepresentations that may have occurred.
Get in Touch
If you're interested in learning more about the class action lawsuit against Agenus or discussing your potential involvement, it’s best to contact The Gross Law Firm. Here’s their contact information:
The Gross Law Firm
The office is located at 15 West 38th Street, 12th floor, New York, NY, 10018
Phone: (646) 453-8903
Frequently Asked Questions
What is the class action lawsuit about?
The class action lawsuit claims that Agenus made misleading statements regarding their immuno-oncology therapies, which significantly impacted investors.
How can I get involved in the class action lawsuit?
You can get involved by registering with the legal firm handling the class action and providing any necessary information.
What’s the deadline for filing claims in this lawsuit?
The deadline to apply for lead plaintiff status is November 5, 2024.
Are there any costs to participate?
There’s no cost or obligation to participate in the class action lawsuit.
Who can I reach out to for more information?
You can contact The Gross Law Firm directly by email or phone to ask about your options and gather more details.
